Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2016

View Archived Issues

Emulate enters translational R&D collaboration

Roche reviews highlights of third quarter 2016

TxCell and UBC begin strategic collaboration to develop CAR-Tregs in solid organ transplantation

BlackThorn Therapeutics closes series A financing

Merck & Co. patents BTK inhibitors

Rigel Pharmaceuticals discloses TGF-beta and/or GDF-8 inhibitors

MedImmune begins phase I study of anti-ILT-7 antibody

AbbVie describes TRPV3 receptor antagonists

FDA approves Zinplava to reduce recurrence of C. difficile infection

FDA approves updated labeling for Xtandi

Gilead Sciences reports results of three phase II studies of selonsertib

Merck & Co.'s KEYNOTE-045 study meets primary endpoint

Daiichi Sankyo updates decision on phase III study of pexidartinib in tenosynovial giant cell tumor

Bristol-Myers Squibb develops IDO inhibitors

Phase II results on OMS-721 in stem cell transplant-associated thrombotic microangiopathy

Daiichi Sankyo reports Japanese phase III results for prasugrel in ischemic cerebrovascular disease

Gilead Sciences provides results from phase III studies of sofosbuvir/velpatasvir/voxilaprevir

Phase III efficacy trials of revefenacin in COPD meet primary endpoint

NeuroVive and Arbutus terminate NVP-018 agreement

FDA committee votes in favor of approving SER-120 for nocturia

FDA accepts resubmitted NDA for safinamide

Phase III study of denosumab in MM meets primary enpoint

VBI-1901 shows promising preclinical results

GSK submits BLA for Shingrix

Janssen presents phase I results for ExPEC4v

Multiplatform imaging of systemic amyloidosis with the new peptide p5+14

New mutations in known disease-associated genes

Discovery of new biomarkers for conditions

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...